•  
  •  
  •  
  •  

2026-07-21 20:44:49

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mastek Reports Q1 FY27 Results: Net Profit Rises 15.3% YoY to ₹106.15 Crore; UK & Europe Operations Lead Growth
  • MedPlus Health Services Reports Q1 FY27 Results: Revenue Up 21.8% YoY to ₹1,879.60 Crore; Net Profit Stands at ₹33.17 Crore
  • Anant Raj Board Approves Strategic Demerger to Create Two Focused Independent Listed Companies
  • Coforge Stands Out as an 'Exceptional Performer' in Application Services and Cloud & Infrastructure Services in Whitelane Research's 2026 UK & Ireland IT Sourcing Study
  • Sagility Limited Reports Strong Q1 FY27 Results: Revenue Surges 27.6% YoY to ₹2,024 Crore; PAT Up 73.5%

Keywords Selected:  USFDA

Stock Report

  • Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years
  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
  • Ajanta Pharma Ltd receives EIR from USFDA for Paithan facility
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Completion of US FDA Pre-Approval Inspection at Eugia Steriles Private Limited
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Tretinoin Cream USP, 0.05%
  • USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Lupin receives approval from U.S. FDA for Ranluspec™ (ranibizumab) Injection
  • Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • Concord Biotech Ltd receives ANDA approval from USFDA for Mycophenolate Mofetil for Oral Suspension USP
  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar

Latest Post

  • Mastek Reports Q1 FY27 Results: Net Profit Rises 15.3% YoY to ₹106.15 Crore; UK & Europe Operations Lead Growth
  • MedPlus Health Services Reports Q1 FY27 Results: Revenue Up 21.8% YoY to ₹1,879.60 Crore; Net Profit Stands at ₹33.17 Crore
  • Anant Raj Board Approves Strategic Demerger to Create Two Focused Independent Listed Companies
  • Coforge Stands Out as an 'Exceptional Performer' in Application Services and Cloud & Infrastructure Services in Whitelane Research's 2026 UK & Ireland IT Sourcing Study
  • Sagility Limited Reports Strong Q1 FY27 Results: Revenue Surges 27.6% YoY to ₹2,024 Crore; PAT Up 73.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025